Active Ingredient(s): Naldemedine
FDA Approved: * March 23, 2017
Pharm Company: * SHIONOGI INC
Category: Opioid Dependence

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Symproic Overview

Naldemedine (INN, USAN; S-297,995) is a peripherally-selective μ-opioid receptor antagonist developed by Shionogi which is approved for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. [1] Clinical studies have thus far found it to possess statistically significant effectiveness for these indications and to be generally well-tolerated with predominantly mild to moderate gastrointestinal side effects.[2][3] No effects indicative of central opioi...

Read more Symproic Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Symproic Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 0.2mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Symproic: (1 result)

Sorted by National Drug Code
  • 59011-523 Symproic .2 mg Oral Tablet by Purdue Pharma Lp

Other drugs which contain Naldemedine or a similar ingredient: (1 result)